In last trading session, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) saw 1.34 million shares changing hands with its beta currently measuring -0.57. Company’s recent per share price level of $3.91 trading at $0.18 or 4.83% at ring of the bell on the day assigns it a market valuation of $346.44M. That closing price of AMLX’s stock is at a discount of -85.93% from its 52-week high price of $7.27 and is indicating a premium of 59.59% from its 52-week low price of $1.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.02 million shares which gives us an average trading volume of 843.76K if we extend that period to 3-months.
For Amylyx Pharmaceuticals Inc (AMLX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.25. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Upright in the green during last session for gaining 4.83%, in the last five days AMLX remained trading in the green while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $3.91 price level, adding 5.1% to its value on the day. Amylyx Pharmaceuticals Inc’s shares saw a change of 3.44% in year-to-date performance and have moved 16.37% in past 5-day. Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) showed a performance of 4.55% in past 30-days. Number of shares sold short was 3.65 million shares which calculate 5.13 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 9 to the stock, which implies a rise of 56.56% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 11. It follows that stock’s current price would drop -2.3% in reaching the projected high whereas dropping to the targeted low would mean a loss of -2.3% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -78.71% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 54.70% while estimates for its earnings growth in next 5 years are of 25.21%.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders
Insiders are in possession of 11.02% of company’s total shares while institution are holding 66.09 percent of that, with stock having share float percentage of 74.28%. Investors also watch the number of corporate investors in a company very closely, which is 66.09% institutions for Amylyx Pharmaceuticals Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at AMLX for having 4.22 million shares of worth $8.03 million. And as of 2024-06-30, it was holding 6.2251 of the company’s outstanding shares.
The second largest institutional holder is AQR CAPITAL MANAGEMENT LLC, which was holding about 3.34 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.9114 of outstanding shares, having a total worth of $6.35 million.
